Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Annals of Hepatology
versión impresa ISSN 1665-2681
Resumen
CHINCHILLA-LOPEZ, Paulina; QI, Xingshun; YOSHIDA, Eric M. y MENDEZ-SANCHEZ, Nahum. The Direct-Acting Antivirals for Hepatitis C Virus and the Risk for Hepatocellular Carcinoma. Ann. Hepatol. [online]. 2017, vol.16, n.3, pp.328-330. ISSN 1665-2681. https://doi.org/10.5604/16652681.1235473.
The increase of incidences of Hepatocellular Carcinoma (HCC) will continue in the next decades. The therapies about hepatitis C infection has been questioned as a risk factor. Some authors emphasized that sustained virologic response (SVR) with interferon- based therapy reduced the risk of developing HCC. In contrast, some publications that to suggest an increasing risk of HCC in patients treated with Direct-Acting Antivirals (DAA). Whether these therapies are associated with an increased risk of HCC remains to be studied and continued long-term observational studies will be needed. The goal in HCV care needs to go beyond merely achieving an SVR.
Palabras llave : Liver; Cancer; Drugs; Hepatitis.